On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025.
News from innovative healthcare startups from Specifica, Aerovate Therapeutics and more.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Targeting the growth factors that influence cell proliferation and differentiation in disease is a pretty “well-trodden” field, but Cambridge biotech Scholar Rock purports to take a new spin on the concept. It’s announced a $20 million Series A financing round, and plans to use the funds to move its preclinical work into clinical drug development. Scholar Rock is […]